P2-391: Scopolamine: Modeling cognitive deficits associated with Alzheimer's disease via novel functional brain imaging and network analysis

Naama Levy-Cooperman, Amit Reches, Denise Milovan, Noga Pinchuk, Guy Ben Bashat, Revital Shani-Hershkovitch, Amir Geva, Leon Y Deouell, Myroslava K Romach, Edward M Sellers

Research output: Contribution to journalArticlepeer-review

Abstract

Scopolamine acts as a muscarinic acetylcholine antagonist at M1 receptors. Evidence showing correlations between Alzheimer's disease (AD) and cholinergic deficits has lead to investigation of scopolamine as a cognitive deficit model. Previously, a dose of 0.4mg scopolamine induced cognitive deficits on tasks of divided attention (DA), vigilance, and short-term memory (STM) in healthy volunteers (Milovan, 2008). The goal of this study was to evaluate scopolamine-induced deficits on measures of electrophysiological activity (P50, P3a/P3b), analyzed using a novel brain network analysis technique (ElMindA), and cognitive tasks of vigilance, DA, STM, and psychomotor skill administered using a computerized cognitive test battery
Original languageEnglish GB
Pages (from-to)S431-S432
JournalAlzheimer's and Dementia
Volume6
DOIs
StatePublished - 2010

Fingerprint

Dive into the research topics of 'P2-391: Scopolamine: Modeling cognitive deficits associated with Alzheimer's disease via novel functional brain imaging and network analysis'. Together they form a unique fingerprint.

Cite this